Pharming Group Past Earnings Performance
Past criteria checks 0/6
Pharming Group's earnings have been declining at an average annual rate of -38.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 5.1% per year.
Key information
-38.4%
Earnings growth rate
-39.2%
EPS growth rate
Biotechs Industry Growth | 14.8% |
Revenue growth rate | 5.1% |
Return on equity | -4.8% |
Net Margin | -4.3% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price
Oct 29Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly
Jun 03Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)
May 12Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
Mar 15Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly
Feb 15Revenue & Expenses BreakdownBeta
How Pharming Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 245 | -11 | 175 | 69 |
30 Sep 23 | 219 | -22 | 160 | 68 |
30 Jun 23 | 206 | -16 | 157 | 60 |
31 Mar 23 | 202 | -2 | 140 | 53 |
31 Dec 22 | 206 | 14 | 127 | 53 |
30 Sep 22 | 204 | 30 | 110 | 69 |
30 Jun 22 | 202 | 21 | 100 | 70 |
31 Mar 22 | 202 | 11 | 94 | 70 |
31 Dec 21 | 199 | 16 | 91 | 65 |
30 Sep 21 | 200 | 22 | 88 | 48 |
30 Jun 21 | 200 | 31 | 83 | 44 |
31 Mar 21 | 202 | 37 | 79 | 41 |
31 Dec 20 | 212 | 38 | 76 | 39 |
30 Sep 20 | 212 | 44 | 75 | 33 |
30 Jun 20 | 202 | 46 | 70 | 32 |
31 Mar 20 | 202 | 42 | 69 | 33 |
01 Jan 20 | 189 | 41 | 66 | 33 |
30 Sep 19 | 175 | 38 | 58 | 38 |
30 Jun 19 | 175 | 34 | 60 | 36 |
31 Mar 19 | 158 | 29 | 55 | 32 |
31 Dec 18 | 155 | 29 | 54 | 33 |
30 Sep 18 | 152 | -29 | 56 | 27 |
30 Jun 18 | 138 | -44 | 53 | 25 |
31 Mar 18 | 128 | -80 | 53 | 24 |
31 Dec 17 | 108 | -91 | 45 | 22 |
30 Sep 17 | 76 | -53 | 32 | 21 |
30 Jun 17 | 47 | -47 | 21 | 20 |
31 Mar 17 | 31 | -21 | 13 | 17 |
31 Dec 16 | 17 | -18 | 8 | 16 |
30 Sep 16 | 12 | -16 | 6 | 17 |
30 Jun 16 | 12 | -15 | 6 | 16 |
31 Mar 16 | 13 | -14 | 6 | 17 |
31 Dec 15 | 12 | -11 | 5 | 15 |
30 Sep 15 | 29 | 8 | 6 | 14 |
30 Jun 15 | 27 | 9 | 5 | 14 |
31 Mar 15 | 23 | 10 | 4 | 13 |
31 Dec 14 | 26 | -7 | 4 | 14 |
30 Sep 14 | 6 | -29 | 3 | 15 |
30 Jun 14 | 6 | -35 | 3 | 14 |
31 Mar 14 | 11 | -35 | 3 | 15 |
31 Dec 13 | 9 | -21 | 3 | 14 |
30 Sep 13 | 19 | -15 | 3 | 18 |
30 Jun 13 | 18 | -19 | 3 | 20 |
Quality Earnings: PHARM is currently unprofitable.
Growing Profit Margin: PHARM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHARM is unprofitable, and losses have increased over the past 5 years at a rate of 38.4% per year.
Accelerating Growth: Unable to compare PHARM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHARM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: PHARM has a negative Return on Equity (-4.82%), as it is currently unprofitable.